About: Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by G. Agnelli et al published 25 June 2007 in Circulation

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2007 (uk) im Juni 2007 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by G. Agnelli et al published 25 June 2007 in Circulation (en)
publication date	wds:Q56680969-896ED650-5E04-4EFE-88EF-3976FBDE8D30
publication date	2007-06-25 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56680969-F7E3675F-CFA7-45FC-B190-0AAB784CFF8D
language of work or name	English
author name string	wds:Q56680969-505CAC06-339B-4D27-8CBA-4776D3638426 wds:Q56680969-5158418C-AB40-4775-BF7F-456AA968AA15 wds:Q56680969-797FC8EF-98BE-43D6-B75D-2ED1247D58BE wds:Q56680969-9BE8F120-CA3F-43BD-885E-B8F09DE64FAD wds:Q56680969-A60865E6-A631-4A81-9616-0CF4DEAC05DD wds:Q56680969-B512F003-3EBC-4BE5-BB0A-C7F0A2156036 wds:Q56680969-D19EAC34-7808-474B-81EA-A285945559DD wds:Q56680969-D77A2CF3-0EE2-4AC3-A251-2C7A1E44CEE8 wds:Q56680969-FCEB8A11-6EA8-4FE7-B3E6-76035AE951C5
author name string	R. D. Hull S. Haas S. Z. Goldhaber M. V. Huisman G. Agnelli A. Gallus A. K. Kakkar F. Misselwitz S. Schellong
rdfs:label	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (nl) Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (en)
skos:prefLabel	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (nl) Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (en)
name	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (nl) Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (en)
author	wds:Q56680969-B3E29787-BCAD-4207-9D08-FCA4E0454EB6
author	Leylagul Kaynar
title	wds:Q56680969-4B85CB48-0200-44F0-AEE8-9B7C3E31BFCE
title	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (en)
page(s)	wds:Q56680969-8778BDD1-488C-4672-803F-C5AEEC017504
page(s)	180-187
instance of	wds:Q56680969-71E31D68-F7D5-41DC-AC9F-9255EEADCD2A
instance of	scholarly article
main subject	wds:Q56680969-55A042B6-528D-4ED0-A6CF-3591645C567F wds:Q56680969-748BB1E6-81F1-41D5-A89A-EAD5F7D60A19
main subject	thrombosis Patients
PubMed ID	wds:Q56680969-45FCDB54-676D-4C9D-9D2E-7FFC7011924C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17576867
PubMed ID	17576867
published in	wds:Q56680969-4BB27F82-2A8F-4926-B85F-37719C0AC65A
published in	Circulation
issue	wds:Q56680969-C511814C-A523-4E8E-A30E-16BE569FA266
volume	wds:Q56680969-FC594FF5-FBE9-4AF5-87AE-2E216E849923
issue	2
volume	116
DOI	wds:Q56680969-4CB1FBD0-5ADC-4860-9E02-90412D6AE519
DOI	http://dx.doi.org/10.1161/CIRCULATIONAHA.106.668020
DOI	10.1161/CIRCULATIONAHA.106.668020
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56680969
is cites work of	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Use of anticoagulants in elderly patients: practical recommendations A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis Rivaroxaban for the treatment of pulmonary embolism Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor Apixaban: a novel oral inhibitor of factor Xa. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents New anticoagulants: A concise review Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis Rivaroxaban: an oral direct inhibitor of factor Xa. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants Acute pulmonary embolism: risk assessment, risk stratification and treatment options. The discovery and development of rivaroxaban. New oral anticoagulants: comparative pharmacology with vitamin K antagonists Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme Practical management of rivaroxaban for the treatment of venous thromboembolism The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Rivaroxaban for the treatment and prevention of thromboembolic disease Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor The quest for new anticoagulants: from clinical development to clinical practice Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects Can patients with femoral neck fracture benefit from preoperative thromboprophylaxis?: A prospective randomized controlled trial Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation Rivaroxaban: a novel, oral, direct factor Xa inhibitor The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Pulmonary embolism: risk assessment and management Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software